ArticleSurgery today2026
Oncological outcomes of omitting axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastasis undergoing mastectomy without radiotherapy.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the oncological outcomes of breast cancer patients with sentinel lymph node (SLN) micrometastases, who underwent mastectomy without axillary lymph node dissection (ALND) or post-mastectomy radiotherapy (PMRT).
methodsThis retrospective single-center study included 79 breast cancer patients with SLN micrometastases who underwent mastectomy, but not completion ALND or PMRT, between 2007 and 2020. We reviewed clinicopathological characteristics, adjuvant systemic therapies, and oncological outcomes. The primary outcome was loco-regional recurrence-free survival (LRFS), and the secondary outcomes included distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS).
resultsThe median age at surgery was 56 years. Most tumors (79%) were estrogen receptor-positive/human epidermal growth factor receptor 2-negative, and approximately 49% were classified as cT1. The median number of removed SLNs was two, and the median number of positive nodes was one. After a median follow-up of 4.8 years, the estimated 5-year LRFS, DDFS, and BCSS were 97.1%, 94.6%, and 95.5%, respectively.
conclusionLow rates of loco-regional recurrence were observed in this retrospective cohort of breast cancer patients with SLN micrometastases, who underwent mastectomy without ALND or PMRT.
Indexed as
Identifiers
42053575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.